World Library  
Flag as Inappropriate
Email this Article

Selank

Article Id: WHEBN0025708188
Reproduction Date:

Title: Selank  
Author: World Heritage Encyclopedia
Language: English
Subject: Anxiolytic, CGS-13767, GBLD-345, SB-205,384, Divaplon
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Selank

Selank
Systematic (IUPAC) name
1-[2-({1-[2-({1-[6-Amino-2-(2-amino-3-hydroxy-butyrylamino)-hexanoyl]-pyrrolidine-2-carbonyl}-amino)-5-guanidino-pentanoyl]-pyrrolidine-2-carbonyl}-amino)-acetyl]-pyrrolidine-2-carboxylic acid
Clinical data
Legal status
  • Unscheduled
Routes Nasal muscosa
Identifiers
ATC code ?
ChemSpider  YesY
Synonyms Selanc; L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-Proline
Chemical data
Formula C33H57N11O9 
Mol. mass 751.9
 YesY   

Selank (Russian: Cеланк) is a nootropic, anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a synthetic analogue of a human tetrapeptide tuftsin.

Pharmacology

Selank is a synthetic analogue of the immunomodulatory peptide tuftsin; as such, it mimics many of its effects. It has been shown to modulate the expression of Interleukin-6 (IL-6) and affect the balance of T helper cell cytokines.[1] It has been shown to influence the concentration of monoamine neurotransmitters[2] and induce metabolism of serotonin.[3][4] There is evidence that it may also modulate the expression of brain-derived neurotropic factor (BDNF) in rats.[5]

Selank, as well as a related peptide drug, semax, have been found to inhibit enzymes involved in the degradation of enkephalins and other endogenous regulatory peptides, and this action may be involved in their effects.[6]

Clinical trials

In clinical trials, the drug has shown to provide a sustained nootropic and anxiolytic effect, which is useful for the treatment of generalized anxiety disorder (GAD).[1] Selank has an advantage over traditional anxiety treatments, such as benzodiazepines, as it has no sedating or cognitive side effects and no associated addiction or withdrawal syndrome. Selank also has very low toxicity with an overdose proving harmless even up to 500 times the effective dose.

As of 2010, the drug has completed stage III clinical trials in Russia and is currently waiting to be authorized for general use in that region. It is unknown if the drug will be marketed in the West or other world regions at this stage.

Selank is closely related to another nootropic drug, Semax, also developed by the Institute of Molecular Genetics in Russia. This drug is currently available in Russian and Ukrainian pharmacies.[7]

As with all lipophilized peptides, it needs refrigeration to remain stable within sterile water solutions, such as bacteriostatic water concentrations.

See also

References

  1. ^ a b Uchakina, O. N.; Uchakin, P. N.; Miasoedov, N. F.; Andreeva, L. A.; Shcherbenko, V. E.; Mezentseva, M. V.; Gabaeva, M. V.; Sokolov, O. U.; Zozulia, A. A.; Ershov, F. I. (2008). "Immunomodulatory effects of selank in patients with anxiety-asthenic disorders". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov 108 (5): 71–75.  
  2. ^ Narkevich, VB; Kudrin, VS; Klodt, PM; Pokrovskiĭ, AA; Kozlovskaia, MM; Maĭskiĭ, AI; Raevskiĭ, KS (2008). "Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study". Eksperimental'naia i klinicheskaia farmakologiia 71 (5): 8–12.  
  3. ^ Semenova, T. P.; Kozlovskiĭ, I. I.; Zakharova, N. M.; Kozlovskaia, M. M. (2010). "Experimental optimization of learning and memory processes by selank". Eksperimental'naia i klinicheskaia farmakologiia 73 (8): 2–5.  
  4. ^ Semenova, T. P.; Kozlovskiĭ, I. I.; Zakharova, N. M.; Kozlovskaia, M. M. (2009). "Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA". Eksperimental'naia i klinicheskaia farmakologiia 72 (4): 6–8.  
  5. ^ Inozemtseva, LS; Karpenko, EA; Dolotov, OV; Levitskaya, NG; Kamensky, AA; Andreeva, LA; Grivennikov, IA (2008). "Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo". Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections / translated from Russian 421: 241–3.  
  6. ^ Kost NV, Sokolov OIu, Gabaeva MV, et al. (2001). "[Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]". Bioorg. Khim. (in Russian) 27 (3): 180–3.  
  7. ^ Institute of Molecular Genetics: Translation of

External links

  • Selank instructions


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.